SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The addition of SGLT-2 inhibitors to the usual management of dietary and lifestyle modifications in Type 2 diabetic patients with NAFLD may potentially prevent disease progression and the various complications that accompany the disease.